Singapore-based biopharmaceutical company Prestige BioPharma Ltd said on Sunday that it has received a positive opinion for an Orphan Drug Designation (ODD) status for its first-in-class anti-PAUF monoclonal antibody PBP1510 for the treatment of pancreatic cancer.
The company received the positive opinion for an ODD status for PBP1510 from the European Medicines Agency's (EMA) Orphan Drug Commission (COMP). The positive opinion will be sent to the European Commission which is expected to grant the orphan designation within 30 days. The manufacturing facilities for global commercial supply are reportedly located in Osong, South Korea.
Through the EMA's ODD status, the company would receive numerous benefits including the exclusive rights to sale for ten years after a successful regulatory approval in the future.
In addition, the company has received PBP1510's ODD status from the US Food and Drug Administration (FDA) and the Korean Ministry of Food and Drug Safety during June and July 2020 respectively.
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Lupin launches Dasatinib tablets in US market
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA
FDA approves Tenpoint Therapeutics' YUVEZZI as first dual-agent eye drop for presbyopia
Summit Therapeutics' BLA for ivonescimab in EGFR-mutated NSCLC accepted by FDA
WuXi Biologics collaborates with Sinorda Biomedicine for antibody development
Biogen's litifilimab receives FDA Breakthrough Therapy Designation for CLE
Glaukos receives FDA approval for repeat administration of iDose TR
Guerbet's contrast agent Elucirem approved by European Commission in children from birth
Spine Innovation's LOGIC Titanium Implant System receives US FDA 510(k) market approval